Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
NewTimeSpace News: On 15 July 2026, Ascletis Pharma(01672.HK) issued an announcement that the Company has selected the fixed-dose combination of ASC48 and ASC30 (ASC30_48 FDC) for clinical development.
The Company plans to file an IND application for oral ASC30_48 FDC tablets with the FDA in the fourth quarter of 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
- Weigao Group(01066.HK): Controlling Shareholder Adds Approximately 15.5988 Million H Shares, Cumulative Share Purchase Hits Around 30.55 Million Shares
- BLACK SESAME (02533.HK): Completes Acquisition of 60% Stake in Target Company to Build Full-Spectrum Edge AI Computing Solutions
- LUNG FUNG GROUP(02290.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 269.1 million, YoY increase of 57.89%
- Shougang LanzaTech (02553.HK): Stabilisation Period Concludes, Over-allotment Option Lapses
